ReviewOrthopaedic surgery2026
Research Progress on Risk Factors for Acute Kidney Injury After Antibiotic-Loaded Bone Cement Spacer Treatment for Periprosthetic Joint Infection.
Review in Orthopaedic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Periprosthetic joint infection (PJI) is a devastating complication of joint arthroplasty and is commonly treated with two-stage revision. During two-stage revision, the insertion of a temporary antibiotic-loaded bone cement spacer (ALCS) in infected joints exerts a direct and effective anti-infection effect but may increase the risk of developing acute kidney injury (AKI). This article reviews the latest research progress on AKI after ALCS insertion for PJI treatment and discusses the definition, incidence and outcome of AKI. We focused on analyzing the risk factors for AKI in terms of demographic characteristics, comorbidities, medication history, perioperative management, and types and doses of antibiotics in ALCS patients. The results revealed that advanced age, excessive obesity, a history of diabetes mellitus, a history of hypertension, the use of angiotensin-converting enzyme inhibitor (ACEI) or angiotensin-II receptor blocker (ARB) medications, a history of chronic kidney disease (CKD), preoperative anemia or hypoalbuminemia, the use of nonsteroidal anti-inflammatory drugs (NSAIDs), high intraoperative blood loss, insufficient perioperative rehydration, and transfusions significantly increased the incidence of AKI. The associations between the development of AKI and antibiotic type and dosage in ALCS are still unclear. Further exploration is still necessary to help clinicians identify PJI patients with a high risk of AKI early and improve their prognosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.